These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 16263755)

  • 21. Self peptide/MHC class I complexes have a negligible effect on the response of some CD8+ T cells to foreign antigen.
    Spörri R; Reis e Sousa C
    Eur J Immunol; 2002 Nov; 32(11):3161-70. PubMed ID: 12555661
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Altered peptide ligands induce delayed CD8-T cell receptor interaction--a role for CD8 in distinguishing antigen quality.
    Yachi PP; Ampudia J; Zal T; Gascoigne NR
    Immunity; 2006 Aug; 25(2):203-11. PubMed ID: 16872849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serial TCR engagement and down-modulation by peptide:MHC molecule ligands: relationship to the quality of individual TCR signaling events.
    Itoh Y; Hemmer B; Martin R; Germain RN
    J Immunol; 1999 Feb; 162(4):2073-80. PubMed ID: 9973480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TGF-beta signaling regulates CD8+ T cell responses to high- and low-affinity TCR interactions.
    Mehal WZ; Sheikh SZ; Gorelik L; Flavell RA
    Int Immunol; 2005 May; 17(5):531-8. PubMed ID: 15824070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spatial coordination of CD8 and TCR molecules controls antigen recognition by CD8+ T-cells.
    Pecht I; Gakamsky DM
    FEBS Lett; 2005 Jun; 579(15):3336-41. PubMed ID: 15913613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The aminopeptidase ERAAP shapes the peptide repertoire displayed by major histocompatibility complex class I molecules.
    Hammer GE; Gonzalez F; Champsaur M; Cado D; Shastri N
    Nat Immunol; 2006 Jan; 7(1):103-12. PubMed ID: 16299505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alloreactive CD8+ T cells can recognize unusual, rare, and unique processed peptide/MHC complexes.
    Malarkannan S; Gonzalez F; Nguyen V; Adair G; Shastri N
    J Immunol; 1996 Nov; 157(10):4464-73. PubMed ID: 8906823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tracking antigen-specific CD8+ T cells in the rat using MHC class I multimers.
    Duplan V; Suberbielle E; Napper CE; Joly E; Saoudi A; Gonzalez-Dunia D
    J Immunol Methods; 2007 Mar; 320(1-2):30-9. PubMed ID: 17223126
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thirty-six views of T-cell recognition.
    Krummel M; Wülfing C; Sumen C; Davis MM
    Philos Trans R Soc Lond B Biol Sci; 2000 Aug; 355(1400):1071-6. PubMed ID: 11186308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anatomic location defines antigen presentation by dendritic cells to T cells in response to intravenous soluble antigens.
    Chung Y; Chang JH; Kim BS; Lee JM; Kim HY; Kang CY
    Eur J Immunol; 2007 Jun; 37(6):1453-62. PubMed ID: 17474148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T cell recognition of self and altered self antigens.
    Nicholson LB; Kuchroo VK
    Crit Rev Immunol; 1997; 17(5-6):449-62. PubMed ID: 9419432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the roles of CD8 alpha alpha and CD8 alpha beta in interaction with MHC class I.
    Sun J; Kavathas PB
    J Immunol; 1997 Dec; 159(12):6077-82. PubMed ID: 9550407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
    Riquelme E; Carreño LJ; González PA; Kalergis AM
    Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct orientation of the alloreactive monoclonal CD8 T cell activation program by three different peptide/MHC complexes.
    Auphan-Anezin N; Mazza C; Guimezanes A; Barrett-Wilt GA; Montero-Julian F; Roussel A; Hunt DF; Malissen B; Schmitt-Verhulst AM
    Eur J Immunol; 2006 Jul; 36(7):1856-66. PubMed ID: 16761314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhancing cytotoxic T cell responses with altered-peptide ligands.
    Zhao R; Collins EJ
    Arch Immunol Ther Exp (Warsz); 2001; 49(4):271-7. PubMed ID: 11726029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dynamic quantification of MHC class I-peptide presentation to CD8+ T cells via intracellular cytokine staining.
    Pang KC; Wei JQ; Chen W
    J Immunol Methods; 2006 Apr; 311(1-2):12-8. PubMed ID: 16516224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The cationic region from HIV tat enhances the cell-surface expression of epitope/MHC class I complexes.
    Leifert JA; Holler PD; Harkins S; Kranz DM; Whitton JL
    Gene Ther; 2003 Dec; 10(25):2067-73. PubMed ID: 14595379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-canonical anchor motif peptides bound to MHC class I induce cellular responses.
    Lazoura E; Lodding J; Farrugia W; Day S; Ramsland PA; Apostolopoulos V
    Mol Immunol; 2009 Mar; 46(6):1171-8. PubMed ID: 19118903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The CD8 beta polypeptide is required for the recognition of an altered peptide ligand as an agonist.
    Renard V; Delon J; Luescher IF; Malissen B; Vivier E; Trautmann A
    Eur J Immunol; 1996 Dec; 26(12):2999-3007. PubMed ID: 8977296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Agonist/endogenous peptide-MHC heterodimers drive T cell activation and sensitivity.
    Krogsgaard M; Li QJ; Sumen C; Huppa JB; Huse M; Davis MM
    Nature; 2005 Mar; 434(7030):238-43. PubMed ID: 15724150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.